Citations

Clear

6273 citation(s) found for "To, Andrew".

Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
Chanan‐Khan, Asher , Agarwal, Amit , Lebovic, Daniel, Darden, David E., Morris, Lura, Munasinghe, Wijith, Zhu, Ming , Enschede, Sari H., Humerickhouse, Rod, Touzeau, Cyrille , Roberts, Andrew W. , Facon, Thierry T.F. , Moreau, Philippe , Ross, Jeremy A. , Salem, Ahmed Hamed , Leverson, Joel D. , Harrison, Simon J

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8580-8580

10.1200/jco.2015.33.15_suppl.8580 Get It

Phase I trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A Children’s Oncology Group Study.
Norris, Robin E. , Fox, Elizabeth , Ralya, Andrew T., Liu, Xiaowei , Ahern, Charlotte H., Dahl, Jodell, Eubank, Rachel, Weigel, Brenda J. , Reid, Joel M. , Minard, Charles G.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 10036-10036

10.1200/jco.2015.33.15_suppl.10036 Get It

CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.
Himelstein, Andrew L., Qin, Rui , Novotny, Paul J. , Seisler, Drew K., Khatcheressian, James, Roberts, John D. , Grubbs, Stephen S., Weckstein, Douglas, Loprinzi, Charles L. , O’Connor, Tracey L. , Shapiro, Charles L.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 9501-9501

10.1200/jco.2015.33.15_suppl.9501 Get It

FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT)
Hulin, Cyrille , Belch, Andrew R. , Reece, Donna , Catalano, John, Qiu, Lugui , Schots, Rik , Marek, Jennifer, Chen, Guang , Ervin‐Haynes, Annette, Facon, Thierry T.F. , Dimopoulos, Meletios Α. , Pinto, Antonio , Ludwig, Heinz , Bahlis, Nizar Jacques , Cavo, Michèle , Moreau, Philippe , Qiu, Lugui , LeBlanc, Richard , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8524-8524

10.1200/jco.2015.33.15_suppl.8524 Get It

Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004
Palumbo, Antonio , Reece, Donna , Sonneveld, Pieter , Spencer, Andrew , Chanan‐Khan, Asher , Goldschmidt, Hartmut , Yeh, Howard, Schecter, Jordan M. , Qin, Xiang , Amin, Himal, Guckert, Mary, Ahmadi, Tahamtan , Dimopoulos, Meletios Α. , Orlowski, Robert Z.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS8609-TPS8609

10.1200/jco.2015.33.15_suppl.tps8609 Get It

Improvements in red blood cell transfusion utilization following implementation of a single‐unit default for electronic ordering
Schaefer, Kalli K., Madde, Nageswar R., Burt, Jennifer M., Higgins, Andrew , Kor, Daryl J. , Madde, Nageswar, Higgins, Andrew A, Warner, Matthew A. , Higgins, Andrew A.

Mayo Clinic

Transfusion | April 19, 2019 | Volume: 59 | Issue: 7 | Pages: 2218-2222

10.1111/trf.15316 | PMID 31002192 Get It

BACKGROUNDThe prevention of excessive allogeneic red blood cell (RBC) transfusion is an important component of patient blood management initiatives. In this investigation, changes in transfusion behaviors following modification of computerized physician order entry (CPOE) procedures for RBC transfusions to a single‐unit default quantity were assessed.STUDY DESIGN AND METHODSThis is an observational cohort study of adults for whom nonemergency allogeneic RBC transfusions were ordered in the 2 years before and 2 years after the date of modification of the CPOE system to a single‐unit default (June 18, 2015). Changes in the frequency of single‐ versus multiunit RBC transfusion orders and other transfusion metrics were compared between preintervention and postintervention cohorts.RESULTSA total of 52,773 unique transfusion orders for 61,989 RBC units were included, of which 60,045 (96.9%) were transfused. Single‐unit orders increased annually, from 10,404 (74.1%) in the first year to 11,645 (88.6%) in the last year, while multiunit orders decreased by more than half (p < 0.0001). The number of RBC units transfused decreased by 13.9% from 32,528 in the preintervention cohort to 27,497 in the post intervention cohort (p < 0.0001) with an estimated reduction in transfusion‐related expenditures of nearly $4 million. The percentage of transfusions associated with a posttransfusion hemoglobin of10 g/dL or greater decreased by 34.5% (p < 0.0001).CONCLUSIONModification of the CPOE process such that nonemergency RBC transfusion orders were defaulted to a single unit was associated with decreased rates of multiunit RBC transfusion orders, lower transfusion volumes, and substantial cost savings.
Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women
Grant, Delores J. , Alberg, Anthony J. , Barnholtz‐Sloan, Jill S. , Bondy, Melissa L. , Funkhouser, Ellen, Moorman, Patricia G. , Peres, Lauren C. , Peters, Edward , Schwartz, Ann G. , Terry, Paul , Wang, Xin‐Qun, Hoyo, Cathrine , Sandler, Dale P. , Taylor, Jack A. , Edwards, Todd L., Beeghly‐Fadiel, Alicia, Wentzensen, Nicolas , Pearce, Celeste Leigh , Wu, Anna H. , Whittemore, Alice S. , McGuire, Valerie , Sieh, Weiva , Rothstein, Joseph H. , Ness, Roberta B., Moysich, Kirsten B. , Rossing, Mary Anne, Sellers, Thomas A. , Monteiro, Álvaro N.A. , Levine, Douglas A. , Haiman, Christopher A. , Menon, Usha , Ramus, Susan J. , Gayther, Simon A. , Terry, Kathryn L. , Goode, Ellen L. , Cannioto, Rikki , Odunsi, Kunle , Etter, John Lewis , Huang, Ruea‐Yea , Bernardini, Marcus Q. , Tone, Alicia , May, Taymaa, Goodman, Marc T. , Thompson, Pamela J., Carney, Michael E. , Tworoger, Shelley S. , Lambrechts, Diether , Vergote, Ignace , Nieuwenhuysen, Els Van , Salvensen, Helga B., Massuger, Leon F.A.G. , Bruegl, Amanda , Moffitt, Melissa , Le, Nhu D. , Brooks‐Wilson, Angela , Kelemen, Linda E. , Song, Honglin , Eccles, Diana , DeFazio, Anna , Kennedy, Catherine J. , Schildkraut, Joellen M. , Lambrechts, Diether , Barnholtz-Sloan, Jill S , Moysich, Kirsten , Permuth, Jennifer B , Cramer, Daniel W , Fazio, Anna de , Lambrechts, Diether , Ramus, Susan J , Sandler, Dale P , Tworoger, Shelley S , Eccles, Diana , Menon, Usha , Monteiro, Alvaro N , Brooks-Wilson, Angela R , Kennedy, Catherine J , Lambrechts, Diether , Sieh, Weiva , Taylor, Jack A , Goodman, Marc T , Manichaikul, Ani , Bandera, Elisa V. , Coté, Michele L. , Keku, Temitope O , Berchuck, Andrew , O’Brien, Katie M. , Edwards, Digna R. Velez , Beeghly‐Fadiel, Alicia , Modugno, Francesmary , Doherty, Jennifer A. , Permuth, Jennifer B. , Setiawan, Veronica Wendy , Marchand, Loı̈c Le , Wilkens, Lynne R. , Karlan, Beth Y. , Gentry‐Maharaj, Aleksandra , Cramer, Daniel W. , Larson, Melissa C. , Kaufmann, Scott H. , Poole, Elizabeth M. , Vanderstichele, Adriaan , Anton‐Culver, Hoda , Ziogas, Argyrios , Brenton, James D. , Bjørge, Line , Kiemeney, Lambertus A. , Pejovic, Tanja B. , Cook, Linda S. , Pharoah, Paul D.P. , Campbell, Ian

Mayo Clinic

Cancer Medicine | April 19, 2019 | Volume: 8 | Issue: 5 | Pages: 2503-2513

10.1002/cam4.1996 | PMID 31001917 Get It

AbstractAn association between genetic variants in the vitamin D receptor (VDR) gene and epithelial ovarian cancer (EOC) was previously reported in women of African ancestry (AA). We sought to examine associations between genetic variants in VDR and additional genes from vitamin D biosynthesis and pathway targets (EGFR, UGT1A, UGT2A1/2, UGT2B, CYP3A4/5, CYP2R1, CYP27B1, CYP24A1, CYP11A1, and GC). Genotyping was performed using the custom‐designed 533,631 SNP Illumina OncoArray with imputation to the 1,000 Genomes Phase 3 v5 reference set in 755 EOC cases, including 537 high‐grade serous (HGSOC), and 1,235 controls. All subjects are of African ancestry (AA). Logistic regression was performed to estimate odds ratios (OR) and 95% confidence intervals (CI). We further evaluated statistical significance of selected SNPs using the Bayesian False Discovery Probability (BFDP). A significant association with EOC was identified in the UGT2A1/2 region for the SNP rs10017134 (per allele OR = 1.4, 95% CI = 1.2‐1.7, P = 1.2 × 10−6, BFDP = 0.02); and an association with HGSOC was identified in the EGFR region for the SNP rs114972508 (per allele OR = 2.3, 95% CI = 1.6‐3.4, P = 1.6 × 10−5, BFDP = 0.29) and in the UGT2A1/2 region again for rs1017134 (per allele OR = 1.4, 95% CI = 1.2‐1.7, P = 2.3 × 10−5, BFDP = 0.23). Genetic variants in the EGFR and UGT2A1/2 may increase susceptibility of EOC in AA women. Future studies to validate these findings are warranted. Alterations in EGFR and UGT2A1/2 could perturb enzyme efficacy, proliferation in ovaries, impact and mark susceptibility to EOC.
Common Habits, Adverse Events, and Opinions Regarding Pre-Workout Supplement Use Among Regular Consumers
Jagim, Andrew R. , Camic, Clayton L., Harty, Patrick S. , Jagim, Andrew R , Harty, Patrick S

Mayo Clinic

Nutrients | April 17, 2019 | Volume: 11 | Issue: 4 | Pages: 855

10.3390/nu11040855 | PMID 31014016 Get It

The purpose of the present study was to examine characteristics of multi-ingredient pre-workout supplement (MIPS) users, their common patterns/habits of MIPS ingestion, and their associated feelings about the effectiveness and safety of this class of supplements. An online electronic survey was distributed through social media to assess self-reported supplementation practices and preferences among adult males and females who reported regular MIPS use. A total of 1045 individuals responded, with 872 of these individuals (males: n = 636, 72.9%; females: n = 233, 26.7%; mean ± SD; age = 27.7 ± 7.9 years; training age = 8.2 ± 7.3 years) completing the survey. The majority of respondents reported the length of current or past MIPS consumption as greater than one year (n = 630, 72.2%), with ingestion frequencies primarily of four (n = 210, 24.1%) or five (n = 212, 24.3%) days per week of training. In addition, the three most popular goals for ingesting MIPS were increased energy and focus (n = 776, 89.0%), muscular endurance (n = 325, 37.3%), and blood flow or “pump” (n = 322, 37.0%). Although most users reported ingesting one serving size with each use, 14% reported ingesting two or more, and 18% indicated they ingest MIPS more than once per day. Importantly, over half (54%) of the respondents reported experiencing side-effects following MIPS use, including skin reactions, heart abnormalities, and nausea. Females were more likely than males to experience these side effects, despite being less likely to consume two or more serving sizes per dose. Our findings also indicated that MIPS users should consume no more than the recommended serving size of a given supplement, as the potentially significant variability in the caffeine content of MIPS products is compounded as more doses are consumed. Furthermore, MIPS users should minimize the ingestion of other supplements which contain high levels of niacin and caffeine, as the concurrent consumption of such products may put users above the tolerable upper limits for these substances.
Fat-Free Mass Index in a Diverse Sample of Male Collegiate Athletes
Currier, Brad S. , Harty, Patrick S. , Zabriskie, Hannah A. , Stecker, Richard A., Moon, Jessica M. , Harty, Patrick S , Zabriskie, Hannah A , Currier, Bradley S , Jagim, Andrew R. , Kerksick, Chad M.

Mayo Clinic

Journal of Strength and Conditioning Research | April 13, 2019 | Volume: 33 | Issue: 6 | Pages: 1474-1479

10.1519/jsc.0000000000003158 | PMID 30985525 Get It

Abstract Currier, BS, Harty, PS, Zabriskie, HA, Stecker, RA, Moon, JM, Jagim, AR, and Kerksick, CM. Fat-free mass index in a diverse sample of male collegiate athletes. J Strength Cond Res 33(6): 1474–1479, 2019—Fat-free mass index (FFMI) is a body composition metric that has been used to assess relative muscularity in athletes. Fat-free mass index is calculated by dividing FFM by height squared, although further height corrections through linear regression may be needed in taller individuals. This study reported height-adjusted FFMI (FFMI Adj ) data in 209 male collegiate athletes from 10 sports (baseball, cross country, football, golf, ice hockey, weightlifting, rugby, swimming, track and field, and water polo) and the FFMI Adj natural upper limit for sports with sufficient sample size. The body composition of all subjects (mean ± SD ; age: 20.7 ± 1.9 years, height: 182.9 ± 6.7 cm, body mass: 90.8 ± 16.8 kg, and percent body fat: 15.6 ± 5.3) was measured using dual-energy x-ray absorptiometry. Linear regression was used to adjust for height, and the FFMI Adj natural upper limit was determined by calculating the 97.5th percentile of all values. One-way analyses of variance with Games-Howell post hoc comparisons were used to determine between-sport differences. A paired-samples t -test revealed a significant difference ( p < 0.001) between unadjusted and adjusted mean FFMI values. The overall mean FFMI Adj was 22.8 ± 2.8 kg·m −2 . Significant between-sport differences ( p < 0.001) in FFMI Adj were identified. Average FFMI Adj was highest in football athletes (24.28 ± 2.39 kg·m −2 ) and lowest in water polo athletes (20.68 ± 3.56 kg·m −2 ). The FFMI Adj upper limit was calculated for all athletes (28.32 kg·m −2 ), rugby (29.1 kg·m −2 ), and baseball (25.5 kg·m −2 ). This study reported FFMI Adj values in a diverse cohort of male collegiate athletes, providing data for the first time in several sports. These values can be used to guide nutritional and exercise interventions, predict athletic performance, and provide coaches with standardized information regarding the potential for further FFM accretion in male athletes.
Cutaneous lesions of angioimmunoblastic T‐cell lymphoma: Clinical, pathological, and immunophenotypic features
Sartori‐Valinotti, Julio C. , Wada, David A., He, Rong , Cappel, Mark A. , Feldman, Andrew L. , Oishi, Naoki , Sartori-Valinotti, Julio C., Feldman, Andrew L , Bennani, N. Nora

Mayo Clinic

Journal of Cutaneous Pathology | April 13, 2019 | Volume: 46 | Issue: 9 | Pages: 637-644

10.1111/cup.13475 | PMID 30980412 Get It

AbstractBackgroundAngioimmunoblastic T‐cell lymphoma (AITL) is a systemic peripheral T‐cell lymphoma with a follicular helper T‐cell (TFH) immunophenotype that frequently involves the skin. However, the histopathology of cutaneous involvement by AITL has not been fully established.MethodsWe reviewed the clinicopathological features of 19 patients seen at our institution with AITL involving the skin. Pan‐T‐cell and TFH marker expression was evaluated by immunohistochemistry. Epstein‐Barr virus (EBV) was detected using in situ hybridization (ISH) for Epstein‐Barr virus‐encoded small RNA (EBER). T‐cell receptor (TCR) gene rearrangement was evaluated by PCR.ResultsAITL affected both trunk and extremities in 15/19 cases (79%). Perivascular infiltration by small and/or medium‐sized lymphocytes was seen in 18/19 (95%). Granulomatous inflammation was identified in 4/19 (21%). Aberrant loss of CD2, CD5, or CD7 was identified in 1/18 (6%), 2/18 (11%), or 7/19 (37%) cases, respectively. Seventeen of eighteen evaluable cases (95%) expressed 2 to 3 TFH markers: PD‐1 in 19/19 (100%), BCL6 in 94% (17/18), and CD10 in 37% (7/19). EBV‐positive cells were detected in 3/18 (17%) with varying density. Clonal TCR gene rearrangement was identified in 9/11 (82%).ConclusionsCutaneous involvement by AITL shows relatively non‐specific histopathological features. However, an immunohistochemical panel including TFH markers and EBER ISH is useful in differential diagnosis.